- Home
- APLT
as 07-26-2024 4:00pm EST
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 555.3M | IPO Year: | 2019 |
| Target Price: | $11.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.18 - $9.39 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -54.84% | Revenue Growth (next year): | 1231.89% |
Stock Insider Trading Activity of Applied Therapeutics Inc. (APLT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shendelman Shoshana | APLT | President and CEO | Jun 6 '24 | Sell | $4.32 | 61,795 | $266,954.40 | 3,756,019 | SEC Form 4 |
| Perfetti Riccardo | APLT | Chief Medical Officer | Jun 6 '24 | Sell | $4.32 | 22,003 | $95,052.96 | 1,009,534 | SEC Form 4 |
| Funtleyder Leslie D. | APLT | Chief Financial Officer | Jun 6 '24 | Sell | $4.32 | 16,980 | $73,353.60 | 291,441 | SEC Form 4 |
| Funtleyder Leslie D. | APLT | Chief Financial Officer | Mar 14 '24 | Sell | $5.39 | 28,727 | $154,838.53 | 308,421 | SEC Form 4 |
| Hansard Adam | APLT | Chief Commercial Officer | Mar 14 '24 | Sell | $5.39 | 48,871 | $263,414.69 | 732,919 | SEC Form 4 |
| Shendelman Shoshana | APLT | President and CEO | Mar 14 '24 | Sell | $5.39 | 318,573 | $1,717,108.47 | 3,817,814 | SEC Form 4 |
| Perfetti Riccardo | APLT | Chief Medical Officer | Mar 14 '24 | Sell | $5.39 | 110,804 | $597,233.56 | 1,031,537 | SEC Form 4 |
| Kanter Stacy J. | APLT | Director | Dec 1 '23 | Buy | $2.18 | 30,000 | $65,367.00 | 63,000 | SEC Form 4 |
| Hansard Adam | APLT | Chief Commercial Officer | Nov 30 '23 | Sell | $1.97 | 965 | $1,901.05 | 381,790 | SEC Form 4 |
Latest Applied Therapeutics Inc. News
APLT Breaking Stock News: Dive into APLT Ticker-Specific Updates for Smart Investing
MT Newswires
25 days ago
Applied Therapeutics Joins Russell 3000 Index
GlobeNewswire
a month ago
Applied Therapeutics Added to Russell 3000® Index
Insider Monkey
a month ago
Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now?
Simply Wall St.
a month ago
Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Compare APLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLT Applied Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.